Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
|Articles|March 2, 2018
PTI Inspection Systems
PTI will showcase MicroCurrent HVLD technology, the optimal inspection method for all parenteral and biologic products at INTERPHEX.
Advertisement
PTI will showcase MicroCurrent HVLD technology, the optimal inspection method for all parenteral and biologic products at INTERPHEX. PTI’s E-Scan 655 is a deterministic, non-destructive test method for prefilled syringes, vials, ampoules, cartridges, and BFS products.
tel. 914.337.2005
info@ptiusa.com
INTERPHEX Booth #3305-A
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement